BPG is committed to discovery and dissemination of knowledge
Featured Articles
6/4/2025 10:28:57 AM | Browse: 326 | Download: 613
Publication Name World Journal of Clinical Cases
Manuscript ID 107279
Country Greece
ISSN 2307-8960 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Surgery
Manuscript Type Minireviews
Article Title Off-label use of treprostinil in adult patients in clinical cases
Manuscript Source Invited Manuscript
All Author List Christina Mouratidou, Efstathios T Pavlidis, Georgios Katsanos, Serafeim-Chrysovalantis Kotoulas, Georgios Tsoulfas, Eleni Mouloudi, Ioannis A Taitzoglou, Ioannis N Galanis and Theodoros E Pavlidis
Funding Agency and Grant Number
Corresponding Author Theodoros E Pavlidis, MD, PhD, Professor, The 2nd Department of Propaedeutic Surgery, Hippokration General Hospital, School of Medicine, Aristotle University of Thessaloniki, Konstantinoupoleos 49, Thessaloniki 54642, Greece. pavlidth@auth.gr
Key Words Treprostinil; Off-label use; Pulmonary hypertension; Digital ischemia; Chronic limb ischemia; Hepatic ischemia–reperfusion injury
Core Tip Treprostinil is a synthetic prostacyclin analog with a stable structure that is currently used for the treatment of pulmonary arterial hypertension. By way of vasodilation and the inhibition of platelet aggregation, treprostinil increases the blood supply in pulmonary circulation and reduces the cardiac workload. In addition to its main indication, several positive reports of off-label treprostinil use in the adult population indicate its benefit in other clinical conditions. Hepatic ischemia–reperfusion injury, chronic limb ischemia, digital ischemia and group 3 and 4 pulmonary hypertension are currently under study as possible indications for treprostinil use outside its approved labeling.
Publish Date 2025-06-04 07:41
Citation

Mouratidou C, Pavlidis ET, Katsanos G, Kotoulas SC, Tsoulfas G, Mouloudi E, Taitzoglou IA, Galanis IN, Pavlidis TE. Off-label use of treprostinil in adult patients in clinical cases. World J Clin Cases 2025; 13(23): 107279

URL https://www.wjgnet.com/2307-8960/full/v13/i23/107279.htm
DOI https://dx.doi.org/10.12998/wjcc.v13.i23.107279
Full Article (PDF) WJCC-13-107279-with-cover.pdf